Literature DB >> 11697831

ESMO recommendations for the application of haematopoietic growth factors (hGFs).

.   

Abstract

Mesh:

Substances:

Year:  2001        PMID: 11697831

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  The safety of full-dose chemotherapy with secondary prophylactic granulocyte colony stimulating factor (G-CSF) following a prior cycle with febrile neutropenia.

Authors:  Nissim Haim; Katerina Shulman; Hadassah Goldberg; Medy Tsalic
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

2.  Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment.

Authors:  Matthias Schwenkglenks; Christian Jackisch; Manuel Constenla; Joseph N Kerger; Robert Paridaens; Leo Auerbach; André Bosly; Ruth Pettengell; Thomas D Szucs; Robert Leonard
Journal:  Support Care Cancer       Date:  2006-04-19       Impact factor: 3.603

Review 3.  The taxanes: toxicity and quality of life considerations in advanced ovarian cancer.

Authors:  J P Guastalla; V Diéras
Journal:  Br J Cancer       Date:  2003-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.